RAMP3 — Receptor Activity Modifying Protein 3
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">RAMP3</th></tr>
<tr><td><b>Full Name</b></td><td>Receptor Activity Modifying Protein 3</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>7p13-p12</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[10269](https://www.ncbi.nlm.nih.gov/gene/10269)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000122679</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9Y5Y9](https://www.uniprot.org/uniprot/Q9Y5Y9)</td></tr>
<tr><td><b>Protein Class</b></td><td>Single-pass membrane protein</td></tr>
<tr><td><b>Expression</b></td><td>Brain, heart, lung, spleen, endothelium</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
Overview
The RAMP3 gene encodes Receptor Activity Modifying Protein 3, a single-pass transmembrane protein that associates with the Calcitonin Receptor-Like Receptor (CALCRL) to form functional receptors for adrenomedullin (AM) and calcitonin gene-related peptide (CGRP)[@maddahi2023]. These peptide hormones play crucial roles in cardiovascular function, neuroprotection, and inflammation.
RAMP3 is expressed throughout the brain and peripheral tissues, with particularly high expression in the cardiovascular system and neuroendocrine tissues. The receptor complexes formed by RAMP3 with CALCRL are involved in diverse physiological processes including vasodilation, cell proliferation, stress response, and neuroprotection[@foord2002].
RAMP Family Overview
The receptor activity-modifying protein (RAMP) family consists of three members:
- RAMP1: Forms CGRP receptors when paired with CALCRL
- RAMP2: Forms AM receptors with CALCRL (vascular type)
- RAMP3: Forms both AM and CGRP receptors with CALCRL
Each RAMP contains a large extracellular N-terminal domain, a single transmembrane helix, and a short cytoplasmic C-terminal tail. The extracellular domain interacts with both the ligand and the GPCR, determining the pharmacology of the receptor complex[@hay2004].
RAMP3-Specific Receptor Complexes
Adrenomedullin Receptor (AM1R): CALCRL + RAMP3
- High affinity for adrenomedullin
- Expressed primarily on endothelial cells and smooth muscle cells
- Mediates vasodilatory and anti-inflammatory effects
CGRP Receptor: CALCRL + RAMP3
- Can also bind CGRP, though with lower affinity than RAMP1-containing receptors
- Mediates neurogenic inflammation and pain signaling
- Important in migraine pathophysiology
The ability of RAMP3 to form both receptor types provides flexibility in tissue-specific signaling responses[@mckeen2010].
Biological Functions
Cardiovascular Effects
RAMP3-mediated signaling has several important cardiovascular effects:
Vasodilation: AM and CGRP cause potent vasodilation through RAMP3-containing receptors
Blood pressure regulation: AM acts as an endogenous vasodilator to modulate blood pressure
Angiogenesis: Promotes formation of new blood vessels
Endothelial protection: Maintains endothelial cell viability and functionThese cardiovascular effects are particularly relevant to cerebrovascular function and [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis, where vascular dysfunction is a key feature[@buo2019].
Neuroprotective Effects
RAMP3 and its ligands have demonstrated neuroprotective properties:
Anti-apoptotic signaling: Activates pro-survival pathways in neurons
Anti-oxidant effects: Reduces oxidative stress in neural tissues
Anti-excitotoxic effects: Protects against glutamate-induced neuronal damage
Blood-brain barrier maintenance: Supports BBB integrityAdrenomedullin, the primary ligand for RAMP3-containing receptors, has been shown to protect against amyloid-beta toxicity in neuronal cultures, suggesting potential therapeutic value in AD[@chu2020].
Immune Modulation
RAMP3 is expressed on immune cells and modulates inflammatory responses:
T-cell function: Regulates T-cell activation and cytokine production
Macrophage polarization: Influences M1/M2 macrophage differentiation
Cytokine regulation: Modulates production of pro-inflammatory cytokines
Neuroinflammation: Affects microglial activation in the brainDysregulation of RAMP3 signaling may contribute to neuroinflammation in neurodegenerative diseases[@terrazzano2019].
Expression Pattern
Tissue Distribution
RAMP3 is widely expressed across tissues:
- Brain: Cerebral cortex, hippocampus, cerebellum, brainstem
- Cardiovascular system: Heart, blood vessels, endothelial cells
- Lung: Bronchial epithelium, alveolar cells
- Spleen: Immune cells
- Kidney: Renal tubular cells
- Adrenal gland: Medullary cells
Within the brain, RAMP3 is expressed in neurons, astrocytes, and microglial cells, where it participates in both physiological signaling and pathological processes[@saxena2002].
Cellular Localization
- Plasma membrane: Primary location for receptor function
- Endoplasmic reticulum: Site of receptor assembly
- Golgi apparatus: Post-translational processing
- Nucleus: Some reports suggest nuclear localization with unknown function
Implications for Neurodegenerative Diseases
Alzheimer's Disease
Multiple lines of evidence connect RAMP3 to [Alzheimer's disease](/diseases/alzheimers-disease):
Vascular hypothesis: RAMP3-mediated vascular dysfunction contributes to vascular cognitive impairment
Amyloid pathology: AM signaling can modulate amyloid precursor protein processing
Tau pathology: RAMP3 expression is altered in tauopathies[@kimura2020]
Neuroinflammation: RAMP3 modulates microglial activation in AD brain
Blood-brain barrier: RAMP3 maintains BBB integrity; dysfunction may increase BBB permeabilityStudies have shown decreased RAMP3 expression in AD brain tissue, which may contribute to the vascular and inflammatory components of the disease[@buo2019].
Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease), RAMP3 may play roles in:
Dopaminergic neuron survival: AM signaling promotes dopaminergic neuron viability
Neuroinflammation: Modulates microglial activation around dopaminergic neurons
Mitochondrial function: May protect against mitochondrial dysfunction
Alpha-synuclein pathology: Potential interaction with protein aggregation pathwaysMigraine and Pain
RAMP3-containing receptors are directly implicated in migraine pathophysiology:
CGRP-mediated signaling: Triggers migraine attacks
Trigeminal ganglion: Expresses RAMP3 and mediates neurogenic inflammation
Vasodilatory effects: CGRP-induced vasodilation of meningeal arteriesCGRP receptor antagonists (gepants) and monoclonal antibodies against CGRP or its receptor have proven effective in migraine prevention and treatment[@onoue2018].
Signaling Pathways
G Protein Coupling
RAMP3-containing receptors couple to multiple G protein subtypes:
- Gs: Activates adenylate cyclase, increases cAMP
- Gq/11: Activates phospholipase C, increases IP3/DAG
- Gi/o: Inhibits adenylate cyclase (cell-type dependent)
The G protein coupling profile depends on the cellular context and RAMP partner[@mckeen2010].
Downstream Effectors
Key signaling pathways activated by RAMP3:
cAMP/PKA: CREB activation, gene transcription
MAPK/ERK: Cell survival and proliferation
PI3K/Akt: Pro-survival signaling
PLC/IP3: Calcium signaling
p38/JNK: Stress responsesTherapeutic Implications
RAMP3-Targeted Therapies
Given the diverse roles of RAMP3 in physiology and disease, several therapeutic approaches are being explored:
RAMP3 agonists: Adrenomedullin analogs for neuroprotection
RAMP3 antagonists: Blockade of detrimental CGRP signaling
CGRP receptor antagonists: Gepants for migraine treatment
Biologic agents: Anti-CGRP antibodies for migraine preventionChallenges
Key challenges in developing RAMP3-targeted therapies:
- Receptor complexity: RAMP3 forms multiple receptor types with different ligands
- Tissue-specific effects: Cardiovascular versus neural effects
- Dosing: Balancing efficacy with potential side effects
- BBB penetration: Targeting brain receptors requires CNS-active compounds
Recent studies have explored intranasal delivery of adrenomedullin analogs as a way to bypass BBB limitations and directly target brain receptors[@takahashi2022].
Research History
1999-2002: Discovery and Characterization
The RAMP family was identified in the late 1990s, with RAMP3 characterized as a protein that modifies the pharmacology of CALCRL. Early studies established the tissue distribution and receptor combinations of RAMP3[@foord2002].
2005-2015: Neurobiology Studies
Subsequent research demonstrated RAMP3 expression in the brain and its roles in neuroprotection, establishing connections to neurological disease. Parthasarathy et al. reviewed the neuroprotective effects of adrenomedullin and CGRP signaling in the brain[@parthasarathy2014].
2016-Present: Therapeutic Development
Recent work has focused on developing RAMP3-targeted therapeutics for migraine, stroke, and neurodegenerative diseases. Clinical trials of CGRP receptor antagonists have shown efficacy in migraine prevention, while preclinical studies explore adrenomedullin analogs for neuroprotection[@onoue2018].
Interaction Network
Protein Partners
RAMP3 interacts with several key proteins:
- CALCRL: Calcitonin receptor-like receptor (primary partner)
- CLR: Alternative name for CALCRL
- RAMP1: Can form heterotrimers in some cell types
- RAMP2: May compete for CALCRL binding
- G proteins: Multiple G protein subtypes (Gs, Gq, Gi)
- Receptor activity-modifying proteins
Genetic Interactions
Bioinformatic analysis reveals genetic interactions with:
- Cardiovascular disease genes
- Migraine susceptibility genes
- [Neurodegeneration](/diseases/neurodegeneration)related genes
See Also
- [CALCRL Gene](/genes/calcrl)
- [ADM Gene](/genes/adm)
- [RAMP1 Gene](/genes/ramp1)
- [RAMP2 Gene](/genes/ramp2)
- [Adrenomedullin Signaling Pathway](/mechanisms/adrenomedullin-pathway)
- [CGRP Signaling in Migraine](/mechanisms/cgrp-migraine-pathway)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [NCBI Gene: RAMP3](https://www.ncbi.nlm.nih.gov/gene/10269)
- [UniProt: RAMP3](https://www.uniprot.org/uniprot/Q9Y5Y9)
- [GeneCards: RAMP3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RAMP3)
References
[Maddahi A, et al., Receptor activity-modifying proteins: physiology and disease relevance (2023)](https://pubmed.ncbi.nlm.nih.gov/36738642/)
[Foord SM, et al., Receptor activity-modifying protein family (2002)](https://pubmed.ncbi.nlm.nih.gov/12037142/)
[Hay DL, et al., RAMPs and the pharmacology of CRLR receptors (2004)](https://pubmed.ncbi.nlm.nih.gov/15046122/)
[McKeown L, et al., RAMP interactions with CLR in cardiovascular physiology (2010)](https://pubmed.ncbi.nlm.nih.gov/20085771/)
[Parthasarathy R, et al., Adrenomedullin and CGRP in neuroprotection (2014)](https://pubmed.ncbi.nlm.nih.gov/24769219/)
[Saxena S, et al., Expression of RAMP in rat brain and peripheral tissues (2002)](https://pubmed.ncbi.nlm.nih.gov/12150960/)
[Buo C, et al., RAMP3 in Alzheimer's disease pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31282408/)
[Iwasawa K, et al., Adrenomedullin signaling in cerebral ischemia (2021)](https://pubmed.ncbi.nlm.nih.gov/33427028/)
[Schvartz D, et al., CGRP and receptor activity in migraine pathophysiology (2020)](https://pubmed.ncbi.nlm.nih.gov/32969506/)
[Chu Y, et al., Adrenomedullin protects against beta-amyloid toxicity (2020)](https://pubmed.ncbi.nlm.nih.gov/32800291/)
[Sato K, et al., RAMP3 deficiency and neuronal dysfunction (2019)](https://pubmed.ncbi.nlm.nih.gov/31247928/)
[Onoue S, et al., CGRP receptor antagonists in migraine treatment (2018)](https://pubmed.ncbi.nlm.nih.gov/29302059/)
[Terrazzano G, et al., RAMP3 in immune modulation and neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/30722786/)
[Iwasaki Y, et al., Adrenomedullin and oxidative stress in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35182947/)
[Hanada T, et al., RAMP3 in BBB maintenance and function (2021)](https://pubmed.ncbi.nlm.nih.gov/33851767/)
[Yuhara K, et al., RAMP3 and cerebrovascular aging (2019)](https://pubmed.ncbi.nlm.nih.gov/30869662/)
[Kimura R, et al., Role of RAMP3 in tau pathology (2020)](https://pubmed.ncbi.nlm.nih.gov/32008532/)
[Onoguchi M, et al., CGRP signaling in neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/33438314/)
[Takahashi K, et al., Adrenomedullin therapy for neurodegenerative disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35217942/)
[Hayashi M, et al., RAMP3 genetic variants and disease susceptibility (2023)](https://pubmed.ncbi.nlm.nih.gov/37014529/)